These Lab-Made Mini-Organs Are Taking the Future of Life Science Research by Storm. Here’s How

Lab-made mini-organs are revolutionizing the future of life science research with their remarkable potential. These tiny, three-dimensional structures, grown from stem cells, closely resemble real human organs. The uses of mini-organs span across various subjects, including disease modeling and drug development, offering unprecedented insights and innovative solutions to some of healthcare’s most challenging problems.

As organoid technology advances, its impact on research and clinical practices is becoming profound. This promises a new era of medical breakthroughs and personalized treatments.

Why Mini-Organs?

There are currently over 103,000 Americans on the organ transplant waiting list, and a new patient is added every eight minutes.¹ Because of the high demand, many people die before receiving a donor organ. Lab-made mini-organs offer a promising solution to this critical issue by potentially providing replacement tissues and organs.

“I saw many patients who could not be treated with transplantation because donors are limited. So, I decided to seek another approach,” says Takanori Takebe, Director for Commercial Innovation of the Center for Stem Cell and Organoid Medicine.²

As organoid technology advances, scientists are exploring ways to grow fully functional organs from a patient's own cells and amniotic fluid, which could be used for transplantation. This approach addresses the donor shortage and reduces the risk of rejection, as the transplanted organs would be biologically compatible with the recipient.

What Are Lab-Made Mini-Organs?

Lab-made mini-organs — also known as organoids — are three-dimensional structures grown from stem cells. They mimic real human organs’ architecture and function. Scientists create them in a laboratory using pluripotent stem cells, which can differentiate into any cell type in the body.³

Researchers carefully manipulate growth conditions to guide the stem cells into forming complex structures that resemble miniaturized versions of organs such as the brain, liver, kidney, and intestines.³ Organoids are a powerful tool for studying human development, disease mechanisms and drug responses in a controlled environment closely mirroring the intricacies of human biology.⁴

One of the most significant advantages of organoids is their ability to model diseases more accurately than traditional two-dimensional cell structures.⁴ For example, brain organoids can develop forms similar to those in the human brain, allowing scientists to investigate neurological disorders like Alzheimer’s disease and autism.

Scientists can use liver organoids to study liver diseases and test the toxicity of new drugs. This enhanced accuracy to actual human organ systems makes them an invaluable resource for medical research, as they can reveal insights into disease progression and potential treatments that might not be observable in animal models or simpler cell cultures.⁴

Organoids also hold great promise for personalized medicine. Creating mini-organs from a patient’s own cells enables researchers to study how specific genetic mutations affect organ function and test customized treatment strategies.⁴ This approach could lead to more effective and tailored therapies for various conditions, from cancer to genetic disorders.

Additionally, scientists can use mini-organs in drug screening and development, significantly reducing the reliance on animal testing and accelerating the discovery of new treatments.⁴ As technology advances, the potential implications of lab-made organoids in research and clinical practice are expected to expand, offering new avenues for understanding and treating human diseases.

The Uses of Mini-Organs in Healthcare

Organoids are revolutionizing healthcare. They’re particularly valuable in disease modeling, where they replicate the complexities of human organs far more accurately than traditional cell cultures.⁴

Researchers can create organoids that mimic diseased tissues, enabling detailed investigations into the progression and underlying mechanisms of illnesses like cancer, cystic fibrosis, and neurodegenerative diseases. This precision allows for a deeper understanding of how diseases develop and respond to various interventions, paving the way for more effective therapies.⁵

In precision medicine, healthcare professionals use mini-organs to tailor treatments to individual patients. By generating organoids from a patient’s own cells, they can observe how specific genetic or environmental factors influence disease and drug response.⁴

For instance, cancer patients can benefit from the technology by having their tumor cells grown into organoids. Cancers are highly variable. Genetic background, stage, and biology differ from patient to patient, making mini-organs a beneficial method for tailoring treatments to each individual.⁵

Healthcare providers can then expose these organoids to different chemotherapy drugs to identify the most effective treatment with the least side effects. This personalized approach ensures therapies are more precisely targeted, improving outcomes and minimizing adverse effects.

Additionally, organoids are instrumental in drug development and testing. They provide a more human-relevant model for assessing efficacy and safety, reducing the reliance on animal models that often fail to accurately predict human responses.⁴

Pharmaceutical companies can use organoids to screen large libraries of compounds, quickly identifying promising candidates for further development. This speeds up the drug discovery process and enhances the likelihood of success in clinical trials.⁴ Moreover, the use of mini-organs extends to studying drug toxicity and side effects in a controlled environment, ensuring that new treatments are effective and safe before they reach the market.⁵

The Endless Potential of Organoids

Lab-made mini-organs significantly enhance the ability to study human diseases and develop new treatments. One of the main benefits is their ability to closely mimic the structure and function of actual human organs.

For instance, brain organoids can develop complex neural networks, while liver organoids can exhibit metabolic functions similar to those of a real liver. This level of detail enables a better understanding of organ development, disease mechanisms and the effects of potential treatments in a more realistic biological context.³

Because organoids can be derived from a patient’s own stem cells, healthcare providers can create a more personalized tissue and organ model. This allows for the study of individual-specific disease processes and the testing of tailored treatment options. A customized approach can lead to improved outcomes, reducing the trial-and-error aspect of treatment.⁶

Traditional drug testing often relies on animal models, which don’t always accurately predict human responses. Mini-organs provide a much more reliable platform for screening potential medications, identifying toxic effects, and understanding interactions. This advantage accelerates drug discovery and reduces the risk of failure in clinical trials, ultimately leading to safer and more effective medications reaching the market more quickly.⁴

Other innovations, such as organoid freezing, have become increasingly viable. A 2022 study demonstrated a simple and effective method using 5% dimethyl sulfoxide (DMSO). This advancement enables organoid preservation and storage, making them more accessible for research and therapeutic applications.⁷ Notably, this technique has shown promise in treating illnesses like interstitial cystitis, with an approved formulation involving a 50% aqueous DMSO solution that healthcare providers instill into the bladder.⁸

The use of mini-organs in drug development is a significant advancement, potentially transforming the pharmaceutical industry and improving healthcare outcomes.

Challenges

Despite their potential, organoids face several challenges. One major issue is the difficulty in replicating the full complexity of human organs. While mini-organs can mimic many aspects of organ function, they often lack complete structural organization and cell diversity in actual human tissues. This limitation can affect their accuracy in disease modeling and drug testing, as certain interactions and responses may not be fully replicated.⁹

Another challenge is the variability of organoid production. Creating them can be inconsistent, leading to variations in size, shape, and cellular composition. This variability can complicate experiments and make obtaining reliable, reproducible results difficult.¹⁰ Researchers must develop more standardized protocols to ensure consistency across different organoid batches, which is crucial for their widespread use in research and clinical applications.

While testing disease progression and new drugs on mini-organs rather than animals is certainly more ethical, there’s still some concern. The creation and use of mini-organs raise questions regarding the source of stem cells and the potential for organoid sentience as their complexity increases.¹¹

Additionally, regulatory frameworks for the use of mini-organs in drug testing and precision medicine are still evolving. Clear guidelines and oversight are needed to ensure organoid research and applications are ethical and safe.

Lastly, integrating organoids into existing medical facilities requires significant investment and adaptation. Developing and maintaining the technology needed to create them can be costly, and healthcare providers need training to use these new tools effectively. Translating research findings into clinical practice can be slow, requiring extensive validation and approval.

Overcoming these logistical and financial barriers is essential for the widespread adoption of organoid technology in healthcare.⁵

Future Implications

Organoids are expected to become even more sophisticated as technology and medicine advance, closely replicating the full complexity of human organs. This will enhance their utility in disease modeling, allowing for more accurate studies of various conditions and the development of targeted therapies.

For instance, improved brain organoids could provide deeper insights into neurological diseases like Parkinson's disease, potentially leading to breakthroughs in treatment and prevention.

As organoid technology becomes more accessible, healthcare systems could use it to create patient-specific models for testing drug responses and treatment strategies. This could revolutionize how healthcare providers treat diseases, moving away from one-size-fits-all approaches to highly customized care plans based on a patient’s unique biological profile.⁵

Lastly, the potential for mini-organs to contribute to regenerative medicine is immense. In the future, researchers might use organoids to grow replacement tissues and transplant organs, addressing the critical donor shortage. Researchers are already exploring ways to upscale organoid production and integrate them with other technologies, such as bioengineering and 3D printing, to create functional tissues and organs.¹²

The Future of Healthcare

The endless uses of mini-organs are transforming the landscape of life science research, providing powerful tools for understanding human biology and developing new treatments. Organoids are at the forefront of medical innovation, from accurately modeling diseases to revolutionizing drug development. The continued research and application of lab-made mini-organs will undoubtedly shape the next generation of healthcare solutions.

References

1. Organ donation Statistics. Organdonor.gov. Published March 1, 2024. https://www.organdonor.gov/learn/organ-donation-statistics
2. Organoids: Today’s research tool, tomorrow’s organ transplant solution. Science. Published March 15, 2024. Accessed June 24, 2024. https://www.science.org/content/article/organoids-todays-research-tool-tomorrows-organ-transplant-solution
3. Kim J. Lo and Behold, the Lab-Grown Organs Have Arrived!. Int J Stem Cells. 2022;15(1):1-2. doi:10.15283/ijsc22026
4. Yang S, Hu H, Kung H, et al. Organoids: The current status and biomedical applications. MedComm (2020). 2023;4(3):e274. Published 2023 May 17. doi:10.1002/mco2.274
5. Bose S, Clevers H, Shen X. Promises and Challenges of Organoid-Guided Precision Medicine. Med. 2021;2(9):1011-1026. doi:10.1016/j.medj.2021.08.005
6. Bose S, Clevers H, Shen X. Promises and challenges of organoid-guided precision medicine. Med. 2021;2(9):1011-1026. doi:10.1016/j.medj.2021.08.005
7. Lee BE, Lee BJ, Lee KJ, et al. A simple and efficient cryopreservation method for mouse small intestinal and colon organoids for regenerative medicine. Biochemical and Biophysical Research Communications. 2022;595:14-21. doi:10.1016/j.bbrc.2021.12.021
8. Gaylord Chemical Company, LLC. Pharmaceuticals - Gaylord Chemical. Gaylord Chemical. Published April 28, 2022. https://www.gaylordchemical.com/markets/pharmaceuticals/
9. Zhou Z, Cong L, Cong X. Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank. Frontiers in Oncology. 2021;11. doi:10.3389/fonc.2021.762184
10. Zhao, Z., Chen, X., Dowbaj, A.M. et al. Organoids. Nat Rev Methods Primers 2, 94 (2022). https://doi.org/10.1038/s43586-022-00174-y
11. Friston K. The sentient organoid? Frontiers in Science. 2023;1. doi:10.3389/fsci.2023.1147911
12. Ren Y, Yang X, Ma Z, et al. Developments and Opportunities for 3D Bioprinted Organoids. Int J Bioprint. 2021;7(3):364. Published 2021 Jun 28. doi:10.18063/ijb.v7i3.364